Eli Lilly and Company LLY is one of the two companies that dominate the booming cardiometabolic space, driven by its successful GLP-1 therapies — Mounjaro for diabetes and Zepbound for weight loss, ...
ReBoost Nasal Spray has been recalled nationwide after tests found mold and bacteria, prompting FDA warnings of possible ...
These habitual market beaters can pull it off again.
The FDA has recalled thousands of Ziac blood pressure tablets after traces of a cholesterol drug were found during testing, ...
The company said some patients had dropped out of the trial because they felt they were losing too much weight.
For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
By Christy Santhosh and Sriparna Roy Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped ...
By Maggie Fick LONDON, Dec 11 (Reuters) - Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish ...
Some patients dropped out of the trial early because they had lost so much weight.
WISH-TV on MSN
New Lilly drug outperforming Zepbound
Stephen Colbert wonders why 'The Late Show' was canceled if Paramount has $108 billion to offer for Warner Bros. Eli Lilly’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback